Showing 2,601 - 2,620 results of 3,004 for search '"Ophthalmology"', query time: 0.05s Refine Results
  1. 2601

    Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment by Guo T, Zhao Y, Liang S, Wang J, Liu H, Zhou Y, Xu H, Chen Z

    Published 2025-01-01
    “…Tingting Guo,1,2,* Yanying Zhao,2,3,* Shengnan Liang,2,3 Jie Wang,2 Hengwei Liu,2 Yufan Zhou,2 Heping Xu,3– 5 Zhongping Chen1– 3,6 1Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 2Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 4Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 5The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK; 6School of Stomatology and Ophthalmology, Xianning Medical College, Xianning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhongping Chen; Heping Xu, Email chenzhongping@csu.edu.cn; heping.xu@qub.ac.ukPurpose: To assess dynamic changes of complement protein in aqueous humor (AH) and plasma of retinal vein occlusion (RVO) patients during ranibizumab treatment, and to explore the differential expression of complement proteins in branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).Patients and Methods: This prospective, consecutive case series study collected AH and plasma samples from 27 RVO patients at baseline, 1 and 2 months after ranibizumab treatment, including 19 BRVO and 8 CRVO patients. …”
    Get full text
    Article
  2. 2602
  3. 2603

    Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study by Helena Norberg, Inger Westborg, Ayat Al-Najjar

    Published 2025-02-01
    “…Further research into the safety profile of faricimab in clinical settings is necessary, along with the consideration of additional eligibility criteria when implementing faricimab in ophthalmology practice.…”
    Get full text
    Article
  4. 2604
  5. 2605
  6. 2606

    Insights and Considerations for “Higher Intraocular Levels of Inflammatory Factors Are Related to Retinal Vascular and Neurodegeneration in Myopic Retinopathy” [Respons... by Zeng L, Yang Z, Li X, Xu H

    Published 2025-02-01
    “…Ling Zeng,1–3 Zhikuan Yang,1–3 Xiaoning Li,1–3 Heping Xu1–5 1Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 2Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 4Aier Eye Institute, Aier Eye Hospital Group, Changsha, People’s Republic of China; 5The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, BT9 7BL, UKCorrespondence: Heping Xu, Email heping.xu@qub.ac.uk Xiaoning Li, Email lixiaoning@aierchina.com…”
    Get full text
    Article
  7. 2607
  8. 2608
  9. 2609
  10. 2610
  11. 2611
  12. 2612
  13. 2613
  14. 2614
  15. 2615
  16. 2616
  17. 2617
  18. 2618
  19. 2619
  20. 2620